株式会社極東書店トップ ＞ 商品一覧 ＞ Data Science, AI, and Machine Learning in Drug Development.
商品詳細
Data Science, AI, and Machine Learning in Drug Development.
・ISBN 978-0-367-70807-8 hard GB£ 145.99
￥46,249.- (税込) ※（※）価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。
| 著者・編者 | Yang, Harry (ed.), |
|---|---|
| シリーズ | (Chapman & Hall/CRC Biostatistics Series) |
| 出版社 | (Chapman & Hall/CRC, UK) |
| 出版年月 | 2022 |
| ページ数 | 320 pp. |
| 言語 | ENG |
| ニュース番号 | ＜A00-91838＞ |
解説
The confluence of big data, artificial intelligence (AI), and machine learning (ML) has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven decisions. Data science stands at a unique moment of opportunity to lead such a transformative change.
Intended to be a single source of information, Data Science, AI, and Machine Learning in Drug Research and Development covers a wide range of topics on the changing landscape of drug R & D, emerging applications of big data, AI and ML in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations.
Features
- Provides a comprehensive review of challenges and opportunities as related to the applications of big data, AI, and ML in the entire spectrum of drug R & D
- Discusses regulatory developments in leveraging big data and advanced analytics in drug review and approval
- Offers a balanced approach to data science organization build
- Presents real-world examples of AI-powered solutions to a host of issues in the lifecycle of drug development
- Affords sufficient context for each problem and provides a detailed description of solutions suitable for practitioners with limited data science expertise